Dataset Information


In vitro drug testing based on contractile activity of C2C12 cells in an epigenetic drug model.

ABSTRACT: Skeletal muscle tissue engineering holds great promise for pharmacological studies. Herein, we demonstrated an in vitro drug testing system using tissue-engineered skeletal muscle constructs. In response to epigenetic drugs, myotube differentiation of C2C12 myoblast cells was promoted in two-dimensional cell cultures, but the levels of contractile force generation of tissue-engineered skeletal muscle constructs prepared by three-dimensional cell cultures were not correlated with the levels of myotube differentiation in two-dimensional cell cultures. In contrast, sarcomere formation and contractile activity in two-dimensional cell cultures were highly correlated with contractile force generation of tissue-engineered skeletal muscle constructs. Among the epigenetic drugs tested, trichostatin A significantly improved contractile force generation of tissue-engineered skeletal muscle constructs. Follistatin expression was also enhanced by trichostatin A treatment, suggesting the importance of follistatin in sarcomere formation of muscular tissues. These observations indicate that contractility data are indispensable for in vitro drug screening.


PROVIDER: S-EPMC5353687 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4605379 | BioStudies
2017-01-01 | S-EPMC5518187 | BioStudies
2012-01-01 | S-EPMC3290432 | BioStudies
2019-01-01 | S-EPMC6771594 | BioStudies
2020-01-01 | S-EPMC7744552 | BioStudies
2012-01-01 | S-EPMC4334564 | BioStudies
2017-01-01 | S-EPMC5724504 | BioStudies
1000-01-01 | S-EPMC6204036 | BioStudies
2017-01-01 | S-EPMC6133580 | BioStudies
2009-01-01 | S-EPMC2775058 | BioStudies